AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06624371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone
Description: Atovaquone oral suspension (750 mg/5mL) will be administered with meals on an outpatient basis.~Patients 13 years and older will receive atovaquone 750 mg PO BID, the standard pediatric dosing for Pneumocystis Jirovecii Pneumonia (PJP) prevention and treatment.~For those aged 2-12 years, atovaquone will be dosed at 30mg/kg once daily. The maximum dose for children under 12 will be 1500 mg.
Study NCT06624371 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 54-60 Gy in 1.8 Gy daily fractions of MRI-guided proton radiotherapy using intensity-modulated pencil-beam scanning technology to match the target will be used.
Study NCT05917210 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard TB-EC
Description: Standard TB-EC by healthcare workers
Study NCT05917210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer navigation strategy for TB-EC
Description: multi-component, peer-navigation strategy for TB-EC
Study NCT05263596 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: dual x-ray absorptiometry, body impedance analysis, muscle strength measurements, ultrasound
Description: Results from the routine geriatric assessment:~* Mini Mental State Exam (MMSE)~* Clock-drawing test (CDT)~* Geriatric depression scale (GDS)~* Functional independence measure (FIM) at admission~* Timed up and go Test (TUG)~* Gait speed~* Hand grip strength (HGS)~* Nutritional risk screening (NRS)~Additional measurements:~* Chair-stand-test~* Clinical frailty scale (CFS)~* Calf circumference and mid-arm circumference~* Body impedance analysis (BIA)~* US~* DXA
Study NCT06645002 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: stevia rebaudiana bertoni
Description: effect of short term study (7 days) of stevia leave powder 1000 mg/day in diabetic subjects
Study NCT06645002 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: stevia rebaudiana bertoni
Description: effect of long term study (60 days) of stevia leave powder 1000 mg/day in diabetic subjects
Study NCT04706910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DOPA
Description: All participants will receive an intravenous injection of 18F-DOPA (4MBq/kg; minimum 110 MBq, maximum 600 MBq) for this study
Study NCT04706910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection
Description: Some participants will receive an intravenous injection of furosemide (40mg, single dose)
Study NCT06206265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRYP-0082
Description: Participants will receive one dose of 25 mg of oral psilocybin on the first dosing day and a second dose of 25mg oral psilocybin on the second dosing day. TRP 8802 will be administered in a comfortable setting under the guidance of the same two therapists from the preparation period. Participants will have an in-person study visit following the resolution of the psychoactive effects of the psilocybin (as determined by the therapists in discussion with the participant) to ensure participant's safety and comfort.
Study NCT06206265 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TRYP-0082
Description: Participants will receive one dose of 25 mg of oral psilocybin on the first dosing day and a second dose of 25mg oral psilocybin on the second dosing day. TRP 8802 will be administered in a comfortable setting under the guidance of the same two therapists from the preparation period. Participants will have an in-person study visit following the resolution of the psychoactive effects of the psilocybin (as determined by the therapists in discussion with the participant) to ensure participant's safety and comfort.
Study NCT06206265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Participants will receive one dose of 25 mg of oral psilocybin on the first dosing day and a second dose of 25mg oral psilocybin on the second dosing day. TRP 8802 will be administered in a comfortable setting under the guidance of the same two therapists from the preparation period. Participants will have an in-person study visit following the resolution of the psychoactive effects of the psilocybin (as determined by the therapists in discussion with the participant) to ensure participant's safety and comfort.
Study NCT06206265 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychotherapy
Description: Participants will receive one dose of 25 mg of oral psilocybin on the first dosing day and a second dose of 25mg oral psilocybin on the second dosing day. TRP 8802 will be administered in a comfortable setting under the guidance of the same two therapists from the preparation period. Participants will have an in-person study visit following the resolution of the psychoactive effects of the psilocybin (as determined by the therapists in discussion with the participant) to ensure participant's safety and comfort.
Study NCT06207838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniMed 780G system
Description: The MiniMed™ 780G system automatically adjust insulin delivery to patient needs for an easier way to stabilise glucose levels. It features an advance level of automation for diabetes management, known as SmartGuard™ technology. If patient glucose levels are trending high, it gives patient more insulin. Technology is CE marked.
Study NCT06202690 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-port robotic-assisted thoracic surgery
Description: All patients : 145 patients Single-port anatomical pulmonary resection(segmentectomy, lobectomy) with a complete mediastinal lymph node dissection will be performed using the SP robotic system.~A 4-cm single incision will be made below the subcostal margin. A chest tube will be inserted in same incision.
Study NCT06202690 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Single-port video-assisted thoracoscopic surgery
Description: All patients : 145 patients Single-port anatomical pulmonary resection(segmentectomy, lobectomy) with a complete mediastinal lymph node dissection will be performed using the VATS.~A 4-cm single incision will be made at 5th intercostal space. A chest tube will be inserted in same incision.
Study NCT06015971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3
Description: Take 2 omega-3 enriched oral supplements per day plus physical activity and Mediterranean Diet
Study NCT06015971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Take 2 hypercaloric hyperproteic oral supplements per day plus physical activity and Mediterranean Diet
Study NCT04670575 — intervention group
Intervention type: PROCEDURE
Intervention: Cataract Surgery with Implantation of Vivity Extended Range of Vision IOL
Description: Patients with early stage glaucoma implanted with Vivity or Vivity Toric IOL
Study NCT06487364 — intervention group
Intervention type: OTHER
Intervention: Rehabilitation
Description: A routine physical therapy program prescribed by a specialist physician and physiotherapist will be applied.
Study NCT05797662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Adults: Propanolol 120 mg tablets by mouth twice daily for up to 24 weeks Children: Propanolol 3 mg/kg suspension, divided dose twice daily for up to 24 weeks
Study NCT04266223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mask-free surface monitoring
Description: Mask-free headrest and couch for patient positioning for radiation therapy combined with a surface monitoring system
Study NCT06477133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: Pre-mixed solution of 2 grams of magnesium sulfate dissolved in 20 mL sterile water
Study NCT05561855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Description: During the 3-month lifestyle intervention period, the participants need to complete the weight monitoring, behavioral goal recording, diet and exercise recording, online course learning by using the WeChat official account module of Weight Loss and Glucose Control.They will receive corresponding feedback and integral rewards every week, and receive monthly follow-ups to complete health education, goal review, motivational interview as well as collecting medication changes and blood glucose monitoring data.
Study NCT05062590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recommendations
Description: Ressources recommendations and interventions curated to the needs of the EP such as refering them to a social activity for socially isolated EP
Study NCT06016556 — intervention group
Intervention type: DRUG
Intervention: nirmatrelvir, ritonavir
Description: single cohort
Study NCT05513690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amnioinfusion at room temperature (intervention arm)
Description: Routine amnioinfusion and intrauterine temperature probe sensor
Study NCT05692258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is a kind of therapy used to treat diseases, in which a needle (usually a millimeter needle) is inserted into a patient's skin or tissue at a certain Angle to stimulate a specific part of the body (acupoint).~Disposable sterile acupuncture filiform needle (0.30mm×25mm、0.30mm×40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.
Study NCT05692258 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture is a kind of therapy used to treat diseases, in which a needle (usually a millimeter needle) is inserted into a patient's skin or tissue at a certain Angle to stimulate a specific part of the body (acupoint).~Disposable sterile acupuncture filiform needle (0.30mm×25mm、0.30mm×40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.
Study NCT05750095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incredible Years Autism Spectrum and Language Delay Programme
Description: Incredible Years Autism Spectrum and Language Delay Programme is a manualised group based intervention in 13 weekly 2-hour sessions. The programme targets parents of children aged 2-6 years, with autism spectrum disorder or language delay.
Study NCT05750095 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: First Aid for Parents
Description: First Aid for Parents is a program consisting of three full day work-shops targeting communication, interaction and daily living skills for parents of children with autism spectrum disorders
Study NCT06692712 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MELPIDA
Description: Gene Therapy agent
Study NCT06692114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Transcranial Magnetic Stimulation, DTMS active
Description: The treatment plan is to perform 2 treatments per day for 20 minutes each time, for a total of 28 treatments. Each treatment stimulates at a frequency of 20 Hz for 2 seconds, with a sequence interval of 20 seconds. Each treatment consists of 50 sequences, for a total of 2000 pulses.
Study NCT06692114 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Transcranial Magnetic Stimulation, DTMS sham
Description: The treatment plan is to perform 2 treatments per day for 20 minutes each time, for a total of 28 treatments. Compared with active treatment, the sham stimulation coil only produced sound and scalp vibration.
Study NCT06596187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous passive motion device (CPM) of ankle - fast
Description: Continuous passive motion device (CPM) of ankle at 1HZ(60rpm) for 10 repetitions
Study NCT06693453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture and Dry cupping
Description: This group will perform electroacupuncture for 20 minutes daily (10 sessions over 2 weeks) and dry cupping for 7 minutes every 4 days (3 sessions over 2 weeks)
Study NCT06693453 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Electroacupuncture and Sham Dry cupping
Description: This group will perform Electroacupuncture for 20 minutes daily (10 sessions over 2 weeks) and Sham Dry cupping for 7 minutes every 4 days (3 sessions over 2 weeks)
Study NCT06692634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mechanical ventilation setting
Description: VT reduction, EIP setting, RR reduction, and a new EIP programing.
Study NCT06693232 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mobile micro-learning
Description: Mobile micro-learning intervention contains a 10-minute video about cardiopulmonary resuscitation to continuously improve their self-confidence, motivation and reduce their stress
Study NCT06693388 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 2 minutes each exercise with 30 sec break - 4 exercises prior to serial casting
Study NCT06693388 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole-Body Vibration
Description: WBV prior to serial casting
Study NCT05280639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wooden block
Description: Individuals randomized to this group will be given a wooden block at no cost to them and a simplified version of home, self-guided exercises with instructions on how to do the exercises and how often to do so.
Study NCT05280639 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Formal physical therapy or Home Exercise Program
Description: Individuals randomized to this group will receive the standard formal physical therapy which are sessions run by a physical therapist, usually 2-3 times a week to rehabilitate their ankle OR follow a standardized home exercise program which will be done by yourself with exercise outlined with how they should be performed and how often
Study NCT06693388 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serial Casting
Description: Serial Casting as provided by standard of care
Study NCT06693206 — intervention group
Intervention type: OTHER
Intervention: Evaluation of aerobic capacity
Description: A stepwise protocol will be used in which the load increases gradually with the bicycle ergometer. In these protocols, the load increases continuously in small amounts throughout the exercise.
Study NCT06747468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avexitide
Description: Avexitide (also known as exendin 9-39), a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, is a 31-amino acid peptide with a free amino group at the N-terminus and an amidated C-terminus. By binding to the GLP-1 receptor, avexitide inhibits GLP-1 receptor signaling, thereby reducing GLP-1 receptor-mediated insulin secretion
Study NCT04734704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin swabs at lesional and non-lesional sites
Description: It will be examined in patients skin swabs sampled at lesional and non-lesional sites
Study NCT04734704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin swabs on skin
Description: It will be examined in patients skin swabs sampled on skin
Study NCT04953351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive registration targeted biopsy and TRUS-system biopsy
Description: Cognitive registration is a visual guidance technique in which the surgeon samples a visually estimated location on ultrasound that corresponds to the MRI suspicious regions location. TRUS-system biopsy includes 12 biopsy cores.
Study NCT04953351 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI-ultrasound fusion targeted biopsy and TRUS-system biopsy
Description: MRI-ultrasound fusion targeted biopsy is conducted with an mpMRI-TRUS biopsy system that provides realtime fusion of TRUS images and MRI images to guide the biopsy needles. TRUS-system biopsy includes 12 biopsy cores.
Study NCT04449510 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electronic Cigarette
Description: E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W. The device will be set at 10 watts for the study visits.
Study NCT06747468 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo comparator
Study NCT05535231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turmeric test product
Description: 2 capsules of 490 mg Turmeric are taken with water once
Study NCT05535231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Turmeric comparator
Description: 2 capsules of 200 mg Turmeric are taken with water once
Study NCT06748079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC3721 inhalation powder
Description: TQC3721 is a target inhibitor.
Study NCT06748079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for TQC3721 inhalation powder
Description: Placebo without drug substance.
Study NCT05013034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab Injection
Description: Subjects will be given IV dosing with basiliximab up to a maximum of 2 treatments (day 0 and day 4) for all patients on study. Treatment for patients may stop for unacceptable side-effects, the Investigator's, or patient's decision to discontinue treatment or other reasons. Exclusion for second dose is first dose returned patient to SpO2 ≥94% on room air.
Study NCT05013034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given IV dosing with placebo (1/2 normal saline) up to a maximum of 2 treatments (day 0 and day 4) for all patients on study. Treatment for patients may stop for unacceptable side-effects, the Investigator's, or patient's decision to discontinue treatment or other reasons. Exclusion for second dose is first dose returned patient to SpO2 ≥94% on room air.
Study NCT05964205 — intervention group
Intervention type: OTHER
Intervention: Electronic clinical decision support tool
Description: Electronic clinical decision support tool
Study NCT05529927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sustained-release Dexamphetamine
Description: During the first week, patients will be individually titrated to the target dose of 90 mg/day, if tolerated. From the second week onwards, patients are prescribed 3 tablets (30 mg) per day, if tolerated. Titration can be slower but should be finished at the end of week 4. After 4 weeks dosages can no longer be increased, and only be reduced.~Patients will visit the treatment centre 2 times per week to take their study medication under supervision of the treatment staff and to receive take-home medication for the days in between study visits.~After 24 weeks patients will be randomized to either (double-blind) continuation or discontinuation (placebo) of SR-Dexamphetamine treatment to assess the consequences of discontinuation, during a 6 weeks period.
Study NCT05529927 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dispensed under the same conditions and with similar frequency as the investigational product (see above).~After 24 weeks study medication will be discontinued in the placebo group.
Study NCT05345873 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E
Description: one dose of SCTV01E on D0, intramuscular
Study NCT05345873 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273
Description: one dose of mRNA-1273 on D0, intramuscular
Study NCT04560543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: McCall suture
Description: Laparoscopic suture including the uterosacral ligaments and the peritoneum
Study NCT04560543 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard cuff closure
Description: Standard laparoscopic barbed suture of the vaginal cuff
Study NCT03816319 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo urine and blood sample collection
Study NCT05220917 — intervention group
Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: Any SGLT2i dispensing claim
Study NCT05220917 — intervention group
Intervention type: DRUG
Intervention: DPP-4 inhibitor
Description: Any DPP-4 inhibitor claim
Study NCT05220917 — intervention group
Intervention type: DRUG
Intervention: GLP-1RA
Description: Any SGLT2i dispensing claim
Study NCT05220917 — intervention group
Intervention type: DRUG
Intervention: 2nd generation SU
Description: Any 2nd generation SU claim
Study NCT04724980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRGN-2012
Description: In the Phase 1, 3+3 dose escalation clinical trial evaluating PRGN-2012 at two dose levels (1x10\^11 and 5x10\^11 particle units (PU)) administered as adjuvant therapy prior to standard-of-care debulking surgery.~In the Phase 2 segment, PRGN-2012 is evaluated at the RP2D.
Study NCT04754555 — intervention group
Intervention type: OTHER
Intervention: Arm Activity Measure (ArmA) in french
Description: The Arm Activity Measure (ArmA) provides a standardized assessment of upper limb passive and active perceived performance
Study NCT05166343 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Epinephrine Injection
Description: Epinephrine administered via sterile epinephrine injection USP, by 0.3mg or 0.5mg epinephrine auto-injector(s) and/or pre-filled syringe (exact dose).
Study NCT06079593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gasless Macular hole surgery
Description: Pars plana vitrectomy to treat full thickness macular hole, with internal limiting membrane flap and ophthalmic viscosurgical device covering
Study NCT06079593 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Macular hole surgery
Description: Pars plana vitrectomy to treat full thickness macular hole, with internal limiting membrane peel, and C2F6 tamponade
Study NCT05407194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Collagen + vitamin C
Description: Participants take the supplement (or placebo) every day for 24 weeks. On three days per week they perform tendon loading exercises.